68 related articles for article (PubMed ID: 21406657)
1. Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
Moelans CB; van Diest PJ
J Natl Cancer Inst; 2011 Apr; 103(8):698-9. PubMed ID: 21406657
[No Abstract] [Full Text] [Related]
2. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
Schmidt C
J Natl Cancer Inst; 2011 Jan; 103(2):87-9. PubMed ID: 21191114
[No Abstract] [Full Text] [Related]
3. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
4. Current status of HER2 testing: caught between a rock and a hard place.
Schnitt SJ; Jacobs TW
Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
[No Abstract] [Full Text] [Related]
5. Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies.
Arena V; Pennacchia I; Monego G; Carbone A; Capelli A
J Clin Oncol; 2010 Feb; 28(5):e83-4; author reply e85-8. PubMed ID: 20065180
[No Abstract] [Full Text] [Related]
6. Human epidermal growth factor receptor 2 testing in breast cancer.
Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
[No Abstract] [Full Text] [Related]
7. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Egervari K; Szollosi Z; Nemes Z; Kaczur V
Am J Clin Pathol; 2006 Jan; 125(1):155-6. PubMed ID: 16483004
[No Abstract] [Full Text] [Related]
8. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.
Altaha R; Crowell E; Hobbs G; Higa G; Abraham J
Cancer; 2005 Feb; 103(3):442-3. PubMed ID: 15578684
[No Abstract] [Full Text] [Related]
9. HER2 Intermediate Breast Cancers.
Jensen KC; Nielsen TO; Gilks CB; West RB
Am J Surg Pathol; 2009 Nov; 33(11):1739; author reply 1739-40. PubMed ID: 19745698
[No Abstract] [Full Text] [Related]
10. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
11. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.
Park IH; Kwon Y; Ro JY; Lee KS; Ro J
Breast Cancer Res Treat; 2010 Aug; 123(1):125-8. PubMed ID: 19916047
[TBL] [Abstract][Full Text] [Related]
12. Importance of accurate HER2 testing in patients with metastatic breast cancer.
Gonzalez-Angulo AM
Clin Adv Hematol Oncol; 2010 Dec; 8(12):873-4. PubMed ID: 21326164
[No Abstract] [Full Text] [Related]
13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
14. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.
Rhodes A; Sarson J; Assam EE; Dean SJ; Cribb EC; Parker A
Am J Clin Pathol; 2010 Oct; 134(4):621-32. PubMed ID: 20855644
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
[TBL] [Abstract][Full Text] [Related]
17. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?
Hameed O; Chhieng DC; Adams AL
Am J Clin Pathol; 2007 Nov; 128(5):825-9. PubMed ID: 17951206
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden.
Rydén L; Haglund M; Bendahl PO; Hatschek T; Kolaric A; Kovács A; Olsson A; Olsson H; Strand C; Fernö M;
Acta Oncol; 2009; 48(6):860-6. PubMed ID: 19353340
[TBL] [Abstract][Full Text] [Related]
19. Anthracyclines in the treatment of HER2-negative breast cancer.
Paik S; Taniyama Y; Geyer CE
J Natl Cancer Inst; 2008 Jan; 100(1):2-4. PubMed ID: 18159066
[No Abstract] [Full Text] [Related]
20. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
Hicks DG; Tubbs RR
Hum Pathol; 2005 Mar; 36(3):250-61. PubMed ID: 15791569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
